Michael J. Boulware

TL;DR: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self‐expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months.

TL;DR: The presence of computed tomographic imaging abnormalities of aortic bioprostheses were frequent but dynamic in the first year after self-expanding transcatheter and surgical aortsic valve replacement, but these findings did not correlate with aorti valve hemodynamic status after aortIC valve replacement in patients at low risk for surgery.

TL;DR: The degree of AoV angulation does not affect early clinical outcomes self-expanding transcatheter aortic valve replacement and there were no linear trends in the frequencies of device success, procedural success, frequencies of moderate or greater aorti regurgitation at 30 days, number of valves implanted, or need for balloon post-dilation or new pacemakers among the AoV angle septiles.

TL;DR: TAVR provided EUS patients significant hemodynamic relief with both 1-year survival and quality of life outcomes comparable to Pivotal and CAS patients, and pre-procedural mean gradient was the only hemodynamic independent predictor of 1- year mortality by multivariate analysis.

TL;DR: In this article, the Hemodynamic performance of prostheses after transcatheter aortic valve replacement (TAVR) is generally better than after SVR, especially in patients.